POWERED BY

NEWS

 

Download PDF

*Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs.  Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple litigations/IPRs are counted more than once.  Within each litigation a claim is counted only once.  Within each IPR, claims are counted only once, whether they are challenged under § 102, § 103, or both.  IPR2017-00826 and -01008 are counted as one IPR, IPR2017-00827 and -01009 are counted as one IPR.  Claims in litigations are determined based on claims alleged infringed in Complaints.

 

Click on the “Subscribe” link above for access to future product dashboards and updates.

METHODOLOGY

Information contained in the Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics Graphics are compiled from information contained in the Fitzpatrick BiologicsHQ database.

DISCLAIMER

BiologicsHQ and materials published on BiologicsHQ are published for informational purposes only. Neither the information nor any opinion expressed on BiologicsHQ constitute legal advice, create an attorney-client relationship, or constitute a solicitation for business. Links or references to third party sites or resources are provided for informational purposes only.

SUBSCRIBE FOR FUTURE UPDATES

captcha